There are a number of other compounds—acquired from Polymedix—in pre-clinical. I believe some of them have shown quite a bit of promise in treating gram neg. bugs. Also anti-fungal drugs. From what I remember reading, the polymedix pipeline was actually pretty impressive in the sheer number of different compounds they had in the works. One cash deal could open up more advanced testing of other compounds.

Don't know much about Poly's inability to get financing for P III. Other than that they chose to follow through on the wrong drug and messed up the dosage of whatever they were calling "B" at the time...don't remember all the details.